{"database":"ENA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics","Multiomics"],"center_name":["University of Michigan"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA131527"],"long_description":["Systemic lupus erythematosus (SLE) is characterized by increased vascular risk due to premature atherosclerosis independent of traditional risk factors. We previously proposed that interferon-α plays a crucial role in premature vascular damage in SLE. IFN-α alters the balance between endothelial cell apoptosis and vascular repair mediated by endothelial progenitor cells (EPCs) and myeloid circulating angiogenic cells (CACs). Here we demonstrate that IFN-α promotes an antiangiogenic signature in SLE and control EPCs/CACs, characterized by transcriptional repression of IL-1α and β, IL-1 receptor 1 and vascular endothelial growth factor A (VEGF-A) and upregulation of IL-1 receptor antagonist (IL-1RN) and the decoy receptor IL1-R2. IL-1β promotes significant improvement in the functional capacity of lupus EPCs/CACs, therefore abrogating the deleterious effects of IFN-α. We used microarrays to analyze the effect of IFNα on peripheral blood EPCs/CACs and on bone marrow EPCs exposed to proangiogenic stimulation. This SuperSeries is composed of the SubSeries listed below. Overall design: Human healthy and lupus EPCs and CACs from PBMCs, and healthy EPCs from bone marrow, were isolated and cultured under proangiogenic stimulation after IFN-α incubation or not, RNA was extracted and processed for hybridization on Affymetrix microarrays."],"tag":["xref:PubMed:20805419","xref:PubMed:22058412"],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"","description":"Expression data from human healthy and lupus EPCs/CACs, and healthy CD133+ bone marrow EPCs","dates":{"last_updated":"2025-09-24","first_public":"2013-05-31"},"accession":"PRJNA131527","cross_references":{"GEO":["GSE23203"],"PubMed":["20805419","22058412"]}}